GLYCOPYRROLATE MSDS PDF

SAFETY DATA SHEET. PRODUCT: Glycopyrrolate Injection USP. Section 1: PRODUCT AND COMPANY INFORMATION. 54/1, Boodhihal village,. Nelamangala. Glycopyrrolate. 1-Methylpyrrolidyl alpha-phenylcyclopentaneglycolate methobromide;. Glycopyrrolate bromide; Glycopyrronium bromide. Glycopyrronium (as the bromide salt glycopyrrolate) is a synthetic anticholinergic agent In October , glycopyrrolate was approved by the FDA for use as a FDA label. Download ( KB). MSDS. Download ( KB).

Author: Mooguran Kazijinn
Country: Peru
Language: English (Spanish)
Genre: Music
Published (Last): 25 September 2015
Pages: 399
PDF File Size: 7.79 Mb
ePub File Size: 15.45 Mb
ISBN: 919-7-20888-384-7
Downloads: 61171
Price: Free* [*Free Regsitration Required]
Uploader: Tudal

Glycopyrronium as the bromide salt glycopyrrolate is a synthetic anticholinergic agent with a quaternary ammonium structure. A muscarinic competitive antagonist used as glycopyrrolste antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics.

For use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and free acidity of gastric secretions and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. Also used to treat chronic obstructive pulmonary disease COPD. Glycopyrrolate decreases acid secretion in the stomach.

Hence it can be used for treating ulcers in the stomach and small intestine, in combination with other medications. In anesthesia, glycopyrrolate injection serves as a preoperative antimuscarinic operation that reduces salivary, tracheobronchial, and pharyngeal secretions, as well as decreases the acidity of gastric secretions blocks cardiac vagal inhibitory reflexes during intubation. Glycopyrrolate binds competitively to the muscarinic acetylcholine receptor.

Like other anticholinergic antimuscarinic agents, it inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, exocrine glands and, to a limited degree, in the autonomic ganglia.

Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions. Side effects include dry mouth, difficult urinating, heachaches, diarrhea and constipation.

The medication also induces drowsiness or blurred vision. Patent US, issued August 20, Drug created on June 13, Glycopyrronium Targets 3 Biointeractions 3. Drug Interaction 1,Phenanthroline The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with 1,Phenanthroline.

Abediterol The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Abediterol. Acebutolol The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Acebutolol. Aclidinium The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Aclidinium.

Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Glycopyrronium. Adrafinil The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Adrafinil. Agmatine Glycopyrronium may increase the anticholinergic activities of Agmatine. Ajulemic acid The risk or severity of Tachycardia and drowsiness can be increased when Glycopyrronium is combined with Ajulemic acid.

Alcuronium Glycopyrronium may increase the anticholinergic activities of Alcuronium. Alfentanil The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Alfentanil. Alphacetylmethadol The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Alphacetylmethadol.

Alphaprodine The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Alphaprodine. Aluminum sulfate The therapeutic efficacy of Aluminum sulfate can glycopyrrolte decreased when used in combination with Glycopyrronium.

  MAHARASHTRA KILLE PDF

Amantadine Amantadine may increase the anticholinergic activities of Glycopyrronium. Ambenonium The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Ambenonium. Amibegron The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Amibegron. Amikacin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Amikacin.

Amitraz The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Amitraz. Amitriptyline The risk glycoyprrolate severity of adverse effects can be increased when Amitriptyline is combined with Glycopyrronium. Amobarbital Glycopyrronium may increase the anticholinergic activities of Amobarbital. Amoxapine Mxds risk or severity of adverse effects can be increased when Amoxapine is combined with Glycopyrronium.

Amphetamine The risk or severity of Tachycardia can be increased when Amphetamine is combined with Glycopyrronium. Anagrelide The risk or severity of Tachycardia can be increased when Anagrelide is glycopyrgolate with Glycopyrronium. Anisodamine The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Anisodamine.

Anisotropine methylbromide The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Glycopyrronium. Apramycin The therapeutic efficacy of Glycopyrorlate can be decreased when used in combination with Apramycin. Aprobarbital Glycopyrronium may increase the anticholinergic activities of Aprobarbital.

Aprotinin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Aprotinin. Arbekacin The mssd efficacy of Glycopyrronium can be decreased glycopyrrolatee used in combination with Arbekacin. Arbutamine The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Arbutamine. Arformoterol The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Arformoterol.

Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Glycopyrronium. Atenolol The bioavailability of Atenolol can be glycopryrolate when combined with Glycopyrronium. Atomoxetine The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Glycopyrronium.

Atracurium Glycopyrronium may increase the anticholinergic activities of Atracurium. Atracurium besylate Atracurium besylate may increase the anticholinergic activities of Glycopyrronium.

Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Glycopyrronium. Bambuterol The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Bambuterol. Barbital Glycopyrronium may increase the anticholinergic activities of Barbital. Barbituric acid derivative Glycopyrronium may increase the anticholinergic activities of Barbituric acid derivative.

Befunolol The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Befunolol. Bekanamycin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Bekanamycin. Benactyzine Glhcopyrrolate risk or severity of adverse effects can be increased when Benactyzine is combined with Glycopyrronium. Bendroflumethiazide The serum concentration of Bendroflumethiazide can be increased when it is combined with Glycopyrronium. Benzatropine The risk or severity glycoopyrrolate adverse effects can be increased when Benzatropine is combined with Glycopyrronium.

Benzilone The risk or severity of adverse effects can be increased when Benzilone is combined with Glycopyrronium. Benzoic Acid The therapeutic efficacy of Benzoic Acid can be decreased when used glycopyerolate combination with Glycopyrronium. Benzphetamine The risk or severity of Tachycardia can be increased when Benzphetamine is combined with Glycopyrronium.

Benzquinamide The risk or severity glyco;yrrolate adverse effects can be increased when Benzquinamide is combined with Glycopyrronium.

Benzthiazide The serum concentration of Benzthiazide can be increased when it is combined with Glycopyrronium. Bethanidine The risk or severity of Tachycardia can be increased when Bethanidine is combined with Glycopyrronium. Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined msde Glycopyrronium. Bezitramide The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Bezitramide.

  KOBO VOX EREADER MANUAL PDF

Glycopyrronium – DrugBank

Biperiden The risk or severity of adverse effects can be increased when Biperiden is combined with Glycopyrronium. Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Glycopyrronium. Bisoxatin The therapeutic efficacy of Bisoxatin can be decreased when used in combination with Glycopyrronium. Bitolterol The risk or severity of Tachycardia can be increased when Bitolterol is combined with Glycopyrronium. Bornaprine The risk or severity of adverse effects can be increased when Bornaprine is combined with Glycopyrronium.

Glycopyrronium

Botulinum toxin type A The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Botulinum Toxin Type A.

Bromocriptine The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Bromocriptine. Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Glycopyrronium. Bucindolol The gllycopyrrolate or severity of Tachycardia can be increased when Glycopyrronium is combined with Bucindolol. Buclizine The risk or severity of adverse effects can be increased when Buclizine is combined with Glycopyrronium.

Buprenorphine The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Buprenorphine. Bupropion Glycopyrronium may increase the anticholinergic activities of Bupropion. Butabarbital Butabarbital may increase the anticholinergic activities of Glycopyrronium.

Butalbital Butalbital may increase the glyvopyrrolate activities of Glycopyrronium. Butethal Glycopyrronium may increase glycopyrrrolate anticholinergic activities of Butethal. Butorphanol The risk or severity of adverse effects can be increased when Glycopyrronium is mxds with Butorphanol.

Butylscopolamine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Glycopyrronium. Calcium polycarbophil The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Glycopyrronium.

Camylofin The risk or severity of adverse effects can be increased when Camylofin is combined with Glycopyrronium. Cannabidiol The risk or severity of Tachycardia and drowsiness can be increased when Glycopyrronium is combined with Cannabidiol. Capreomycin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Capreomycin. Capsaicin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Capsaicin. Carboxymethylcellulose The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in msdx with Glycopyrronium.

Carfentanil The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Carfentanil. Castor oil The therapeutic efficacy of Castor oil can be decreased when used in combination with Glycopyrronium. glyxopyrrolate

Celiprolol The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Celiprolol. Cetirizine Cetirizine may increase the anticholinergic activities of Glycopyrronium. Chloroprocaine Glycopyrronium may increase the anticholinergic activities of Chloroprocaine.

Chlorothiazide The serum concentration of Chlorothiazide can be increased when it is combined with Glycopyrronium. Chlorphenoxamine The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Glycopyrronium.